Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)

    Lassen, Ulrik Niels, Daugaard, G., Eigtved, A., Damgaard, K. & Friberg, L., Jul 1999, In: European journal of cancer (Oxford, England : 1990). 35, 7, p. 1076-82 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma

    Nedergaard, M. K., Michaelsen, Signe Regner, Urup, T., Broholm, H., El Ali, Henrik H., Poulsen, H. S., Stockhausen, M., Kjær, Andreas & Lassen, Ulrik Niels, 2015, In: P L o S One. 10, 2, p. 1-16 16 p., e0115315.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    A Comparison of Endoscopic Ultrasound Guided Biopsy and Positron Emission Tomography with Integrated Computed Tomography in Lung Cancer Staging

    Larsen, S. S., Vilmann, Peter, Krasnik, K., Dirksen, A., Clementsen, P., Skov, B. G., Jacobsen, G. K., Lassen, Ulrik Niels, Eigtved, A., Berthelsen, A. K., Mortensen, J. & Højgaard, Liselotte, Jan 2009, In: Current Health Sciences Journal. 35, 1, p. 5-12 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

    Lassen, Ulrik Niels, Jensen, L. H., Sorensen, M., Rohrberg, K. S., Ujmajuridze, Z. & Jakobsen, A., 1 Apr 2011, In: Acta Oncologica. 50, 3, p. 448-54 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

    de Weger, V. A., Goel, S., von Moos, R., Schellens, J. H. M., Mach, N., Tan, E., Anand, S., Scott, J. W. & Lassen, Ulrik Niels, 2018, In: Cancer Chemotherapy and Pharmacology. 81, 1, p. 73-80 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers

    Lassen, Ulrik Niels, Meulendijks, D., Siu, L. L., Karanikas, V., Mau-Sorensen, M., Schellens, J. H. M., Jonker, D. J., Hansen, A. R., Simcox, M. E., Schostack, K. J., Bottino, D., Zhong, H., Roessler, M., Vega-Harring, S. M., Jarutat, T., Geho, D., Wang, K., DeMario, M. & Goss, G. D., 15 Jan 2015, In: Clinical Cancer Research. 21, 2, p. 258-66 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

    Holländer, C., Baeksgaard, L., Sorensen, M., Albertsson, P., Damstrup, L. & Lassen, Ulrik Niels, Sep 2012, In: Anticancer Research. 32, 9, p. 4019-23 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

    Mirza, M. R., Bergmann, T. K., Mau-Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E., Birrer, M. J., Jørgensen, M., Roed, H., Malander, S., Nielsen, F., Lassen, Ulrik Niels, Brøsen, K., Bjørge, L. & Mäenpää, J., 2019, In: Cancer Chemotherapy and Pharmacology. 84, 4, p. 791-798 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

    Lassen, Ulrik Niels, Molife, L. R., Sorensen, J. M., Engelholm, S., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P., de Bono, J. S. & Buhl-Jensen, P., 29 Jun 2010, In: B J C. 103, 1, p. 12-7 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

    Mau-Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, Ulrik Niels, Büchler, W., Martinius, H. & Tabernero, J., May 2015, In: Cancer Chemotherapy and Pharmacology. 75, 5, p. 1065-73 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

    Lassen, Ulrik Niels, Nielsen, Dorte Lisbet, Sørensen, M., Winstedt, L., Niskanen, T., Stenberg, Y., Pakola, S., Stassen, J. & Glazer, S., 14 Feb 2012, In: B J C. 106, 4, p. 678-84 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results.

    Lassen, Ulrik Niels, Sorensen, M., Jensen, P., Langer, Seppo W., Jensen, B., Jeppesen, N., Rytter, C., Mellemgaard, A., Hansen, Oddur & Osterlind, K., 15 Jul 2004, In: Journal of Clinical Oncology. 22, 14, p. 667S-667S 1 p.

    Research output: Contribution to journalConference articleResearchpeer-review

  13. Published

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    Cejalvo, J. M., Jacob, W., Fleitas Kanonnikoff, T., Felip, E., Navarro Mendivil, A., Martinez Garcia, M., Taus Garcia, A., Leighl, N., Lassen, Ulrik Niels, Mau-Soerensen, M., Adessi, C., Michielin, F., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2019, In: ESMO Open. 4, 4, 7 p., e000532.

    Research output: Contribution to journalJournal articleResearchpeer-review

  14. Published

    A prospective PET study of patients with glioblastoma multiforme

    Andersen, P. B., Blinkenberg, M., Lassen, Ulrik Niels, Kosteljanetz, M., Wagner, A., Poulsen, H. S., Sørensen, Per Soelberg & Paulson, Olaf B., Jun 2006, In: Acta Neurologica Scandinavica. 113, 6, p. 412-8 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  15. Published

    A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis

    Fischer, Barbara Malene Bjerregaard, Mortensen, J., Langer, Seppo W., Loft, A., Berthelsen, A. K., Petersen, B. I., Daugaard, G., Lassen, Ulrik Niels & Hansen, H. H., Feb 2007, In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 18, 2, p. 338-45 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  16. Published

    A systematic review of targeted agents for non-small cell lung cancer

    Vestergaard, H. H., Christensen, M. R. & Lassen, Ulrik Niels, 2018, In: Acta Oncologica. 57, 2, p. 176-186 11 p.

    Research output: Contribution to journalReviewResearchpeer-review

  17. Published

    Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis

    Tuxen, I. E. V., Mau-Sørensen, M., Yde, C. W., Jønson, L., Oestrup, O., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Journal of Clinical Oncology. 34, 15, Suppl., 1 p., e23256.

    Research output: Contribution to journalConference abstract in journalResearch

  18. Published

    Actively personalized vaccination trial for newly diagnosed glioblastoma

    Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A. & 44 others, Skardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H. G., Singh-Jasuja, H., Sahin, U., Dietrich, P. Y. & Wick, W., 2019, In: Nature. 565, 7738, p. 240-245 6 p.

    Research output: Contribution to journalLetterResearchpeer-review

  19. Published

    Amantadin til influenza

    Lassen, Ulrik Niels & Hornsleth, A., 20 Jul 1992, In: Ugeskrift for Laeger. 154, 30, p. 2099-103 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  20. Published

    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

    Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Dómine, M., Lara, P., Paik, P. K., Lassen, Ulrik Niels, Orlov, S., Trigo, J., Shomova, M., Baker-Neblett, K., Vasquez, J., Wang, X., Yan, L., Mitrica, I., DeYoung, M. P. & Garrido, P., Oct 2019, In: Lung Cancer. 136, p. 74-79

    Research output: Contribution to journalJournal articleResearchpeer-review

  21. Published

    Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Michaelsen, Signe Regner, Olsen, L. R., Toft, A., Christensen, I. J., Grunnet, K., Winther, Ole, Broholm, H., Kosteljanetz, M., Issazadeh-Navikas, Shohreh, Poulsen, H. S. & Lassen, Ulrik Niels, Oct 2016, In: Molecular Oncology. 10, 8, p. 1160-1168

    Research output: Contribution to journalJournal articleResearchpeer-review

  22. Published

    Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Urup, T., Gillberg, Linn, Kaastrup, K., Lü, M. J. S., Michaelsen, Signe Regner, Andrée Larsen, V., Christensen, I. J., Broholm, H., Lassen, Ulrik Niels, Grønbæk, Kirsten & Poulsen, H. S., 2020, In: Molecular Oncology. 14, 5, p. 964-973

    Research output: Contribution to journalJournal articleResearchpeer-review

  23. Published

    Angiotensinogen promoter methylation to predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Gillberg, Linn, Kaastrup, K., Lu, M. S., Michaelsen, Signe Regner, Larsen, V. A., Christensen, I. J., Broholm, H., Lassen, Ulrik Niels, Grønbæk, Kirsten & Poulsen, H. S., 2019, In: Neuro-Oncology. 21, Supplement 6, p. vi149

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  24. Published

    Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Ahlborn, L. B., Rohrberg, K. S., Gabrielaite, M., Tuxen, I. V., Yde, C. W., Spanggaard, I., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Mau-Sorensen, M. & Østrup, O., Feb 2019, In: OncoTarget. 10, 14, p. 1388-1398

    Research output: Contribution to journalJournal articleResearchpeer-review

  25. Published

    Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Toft, A., Urup, T., Christensen, I. J., Michaelsen, Signe Regner, Lukram, B., Grunnet, K., Kosteljanetz, M., Larsen, V. A., Lassen, Ulrik Niels, Broholm, H. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 2, p. 165-174 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  26. Published

    Brain metastases in small-cell lung cancer

    Lassen, Ulrik Niels, Kristjansen, P. E. & Hansen, H. H., Nov 1995, In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 6, 9, p. 941-4 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  27. Published

    Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., Choudhary, S., Gustavsson, T., Dagil, R., Daugaard, M., Sander, A. F., Torp, M. H., Søgaard, M., Theander, T. G., Østrup, O., Lassen, U. & 3 others, Hamerlik, P., Salanti, Ali & Agerbæk, Mette Ørskov, 2019, In: Cells. 8, 9, 21 p., 998.

    Research output: Contribution to journalJournal articleResearchpeer-review

  28. Published

    Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Nørøxe, D. S., Østrup, O., Yde, C. W., Ahlborn, L. B., Nielsen, Finn Cilius, Michaelsen, Signe Regner, Larsen, V. A., Skjøth-Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 2019, In: OncoTarget. 10, 43, p. 4397-4406 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  29. Published

    Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Hasselbalch, B., Lassen, Ulrik Niels, Poulsen, H. S. & Stockhausen, M., 1 Oct 2010, In: Cancer Investigation. 28, 8, p. 775-87 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  30. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  31. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., 1 May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  32. Published

    Changes in key recruitment performance metrics from 2008-2019 in industrysponsored phase III clinical trials registered at ClinicalTrials.gov

    Brøgger-Mikkelsen, Mette, Zibert, J. R., Andersen, A. D., Lassen, Ulrik Niels, Hædersdal, Merete, Ali, Z. & Thomsen, Simon Francis, 2022, In: PLoS ONE. 17, 7 July, p. 1-15 e0271819.

    Research output: Contribution to journalJournal articleResearchpeer-review

  33. Published

    Characteristics of de novo cancer in liver transplant recipients

    Riis, T. H., Møller, D. L., Høgh, J., Knudsen, A. D., Rostved, A. A., Akdag, D., Kirkby, N., Lassen, Ulrik Niels, Rasmussen, A., Hillingsø, Jens Georg & Pommergaard, Hans-Christian L, 2023, In: APMIS. 131, 4, p. 135-141 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  34. Published

    Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579

    Research output: Contribution to journalJournal articleResearchpeer-review

  35. Published

    Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jun 2017, In: Pharmacology Research & Perspectives. 5, 3, 9 p., e00317.

    Research output: Contribution to journalJournal articleResearchpeer-review

  36. Published

    Combining PARP inhibition with PD-1 inhibitors

    Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 9, p. 1196-1198 3 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

  37. Published

    Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome

    Araujo B de Lima, V., Borch, A., Hansen, M., Draghi, A., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, Apr 2020, In: Cytotherapy. 22, 4, p. 204-213 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  38. Published

    Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

    Lazar, V., Raynaud, J., Magidi, S., Bresson, C., Martini, J. F., Galbraith, S., Wunder, F., Onn, A., Batist, G., Girard, N., Lassen, U., Pramesh, C. S., Al-Omari, A., Ikeda, S., Berchem, G., Blay, J. Y., Solomon, B., Felip, E., Tabernero, J., Rubin, E. & 5 others, Philip, T., Porgador, A., Berindan-Neagoe, I., Schilsky, R. L. & Kurzrock, R., 2022, In: Therapeutic Advances in Medical Oncology. 14, p. 1-15 15 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  39. Published

    Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

    Carlson, J. J., Italiano, A., Brose, M. S., Federman, N., Lassen, Ulrik Niels, Kummar, S. & Sullivan, S. D., 2022, In: American Journal of Managed Care. 28, p. S26-S32

    Research output: Contribution to journalJournal articleResearchpeer-review

  40. Published

    Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma

    Nedergaard, M. K., Michaelsen, Signe Regner, Perryman, L., Erler, Janine, Poulsen, H. S., Stockhausen, M., Lassen, Ulrik Niels & Kjær, Andreas, Mar 2016, In: Nuclear Medicine and Biology. 43, 3, p. 198-205 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  41. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journalJournal articleResearchpeer-review

  42. Published

    Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

    Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., Giménez-Capitán, A., Drozdowskyj, A., Viteri, S., Larsen, M. R., Lassen, Ulrik Niels, Felip, E., Bivona, T. G., Ditzel, H. J. & Rosell, R., 2017, In: Nature Communications. 8, 14 p., 410.

    Research output: Contribution to journalJournal articleResearchpeer-review

  43. Published

    Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials

    Tuxen, I. V., Rohrberg, K. S., Oestrup, O., Ahlborn, L. B., Schmidt, A. Y., Spanggaard, I., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Yde, C. W., Mau-Sørensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2019, In: Clinical Cancer Research. 25, 4, p. 1239-1247 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  44. Published

    Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials

    Tuxen, I. V., Yde, C. W., Mau-Sorensen, M., Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Annals of Oncology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  45. Published

    Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies

    Tuxen, I. E. V., Santoni Rugiu, Eric, Joenson, L., Vikesaa, J., Mau-Soerensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2014, In: Journal of Clinical Oncology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  46. Published
  47. Published

    Current therapy of small cell lung cancer

    Sorensen, M., Lassen, Ulrik Niels & Hansen, H. H., Mar 1998, In: Current Opinion in Oncology. 10, 2, p. 133-8 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  48. Published

    Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J-Y., Italiano, A., Yonemori, K., Cho, D. C., de Vos, F. Y. F. L., Moreau, P., Fernandez, E. E., Schellens, J. H. M., Zielinski, C. C., Redhu, S., Boran, A. & 3 others, Passos, V. Q., Ilankumaran, P. & Bang, Y., 2023, In: Nature Medicine. 29, 5, p. 1103-1112 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  49. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Subbiah, V., Lassen, Ulrik Niels, Élez, E., Italiano, A., Curigliano, G., Javle, M., De Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P. & Wainberg, Z. A., 1 Sep 2020, In: The Lancet Oncology. 21, 9, p. 1234-1243 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  50. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

    Subbiah, V., Lassen, Ulrik Niels, Gasal, E., Burgess, P. & Wainberg, Z. A., 1 Nov 2020, In: The Lancet Oncology. 21, 11, p. e516 1 p.

    Research output: Contribution to journalComment/debateResearch

Previous 1 2 3 4 Next

ID: 4952653